Howard Gostfrand's questions to Biostem Technologies Inc (BSEM) leadership • Q2 2024
Question
Howard Gostfrand asked about BioStem's M&A strategy for the next 12 months, considering the company's strengthening cash position and significant growth.
Answer
Executive Jason Matuszewski stated that the company is actively evaluating M&A opportunities that fit within its continuum of care. He specified that they are looking for products that complement their existing perinatal tissue offerings, potentially outside the direct skin substitute realm, to support patients globally. While opportunities are being mined, no specific targets have been identified yet.